{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,4,30]],"date-time":"2026-04-30T20:33:46Z","timestamp":1777581226578,"version":"3.51.4"},"reference-count":71,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2019,11,1]],"date-time":"2019-11-01T00:00:00Z","timestamp":1572566400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2019,11,1]],"date-time":"2019-11-01T00:00:00Z","timestamp":1572566400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"}],"funder":[{"DOI":"10.13039\/501100004663","name":"Ministry of Science and Technology, Taiwan","doi-asserted-by":"publisher","award":["108-2320-B-016-002"],"award-info":[{"award-number":["108-2320-B-016-002"]}],"id":[{"id":"10.13039\/501100004663","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100010425","name":"Tri-Service General Hospital","doi-asserted-by":"publisher","award":["TSGH-C106-120"],"award-info":[{"award-number":["TSGH-C106-120"]}],"id":[{"id":"10.13039\/501100010425","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100010425","name":"Tri-Service General Hospital","doi-asserted-by":"publisher","award":["TSGH-C108-158"],"award-info":[{"award-number":["TSGH-C108-158"]}],"id":[{"id":"10.13039\/501100010425","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["European Journal of Pharmacology"],"published-print":{"date-parts":[[2019,11]]},"DOI":"10.1016\/j.ejphar.2019.172639","type":"journal-article","created":{"date-parts":[[2019,9,3]],"date-time":"2019-09-03T19:06:54Z","timestamp":1567537614000},"page":"172639","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":14,"special_numbering":"C","title":["The effect of dextromethorphan use in Parkinson's disease: A 6-hydroxydopamine rat model and population-based study"],"prefix":"10.1016","volume":"862","author":[{"given":"Cheng-Tsung","family":"Liu","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Li-Ting","family":"Kao","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Jui-Hu","family":"Shih","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Wu-Chien","family":"Chien","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Chuang-Hsin","family":"Chiu","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Kuo-Hsing","family":"Ma","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Yuahn-Sieh","family":"Huang","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Cheng-Yi","family":"Cheng","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Chyng-Yann","family":"Shiue","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"I-Hsun","family":"Li","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"78","reference":[{"key":"10.1016\/j.ejphar.2019.172639_bib1","doi-asserted-by":"crossref","first-page":"234","DOI":"10.2967\/jnumed.114.148619","article-title":"Use of 11C-PE2I PET in differential diagnosis of parkinsonian disorders","volume":"56","author":"Appel","year":"2015","journal-title":"J. Nucl. Med. : Offic. Publ., Soc. Nucl. Med."},{"key":"10.1016\/j.ejphar.2019.172639_bib2","doi-asserted-by":"crossref","first-page":"158","DOI":"10.1016\/j.nucmedbio.2015.11.002","article-title":"PET imaging of dopamine transporters with [(18)F]FE-PE2I: effects of anti-Parkinsonian drugs","volume":"43","author":"Bang","year":"2016","journal-title":"Nucl. Med. Biol."},{"key":"10.1016\/j.ejphar.2019.172639_bib3","doi-asserted-by":"crossref","first-page":"57","DOI":"10.1016\/j.parkreldis.2009.05.005","article-title":"[11C]-PK11195 PET: quantification of neuroinflammation and a monitor of anti-inflammatory treatment in Parkinson's disease?","volume":"16","author":"Bartels","year":"2010","journal-title":"Park. Relat. Disord."},{"key":"10.1016\/j.ejphar.2019.172639_bib4","doi-asserted-by":"crossref","first-page":"1629","DOI":"10.1096\/fj.14-269043","article-title":"Translating dosages from animal models to human clinical trials--revisiting body surface area scaling","volume":"29","author":"Blanchard","year":"2015","journal-title":"FASEB J. : Off. Publ. Federat. Am. Soc. Exp. Biol."},{"key":"10.1016\/j.ejphar.2019.172639_bib5","first-page":"27","article-title":"The symptoms of Parkinson disease","volume":"26 Spec No 3","author":"Bleton","year":"2000","journal-title":"L'Encephale"},{"key":"10.1016\/j.ejphar.2019.172639_bib6","doi-asserted-by":"crossref","first-page":"53","DOI":"10.1016\/0140-6736(92)92466-S","article-title":"Dextromethorphan and parkinsonism","volume":"340","author":"Bonuccelli","year":"1992","journal-title":"Lancet"},{"key":"10.1016\/j.ejphar.2019.172639_bib7","doi-asserted-by":"crossref","first-page":"79","DOI":"10.1023\/A:1014854606309","article-title":"Glutamate-induced excitotoxicity in retina: neuroprotection with receptor antagonist, dextromethorphan, but not with calcium channel blockers","volume":"27","author":"Calzada","year":"2002","journal-title":"Neurochem. Res."},{"key":"10.1016\/j.ejphar.2019.172639_bib8","doi-asserted-by":"crossref","first-page":"206","DOI":"10.1016\/j.drugalcdep.2012.08.025","article-title":"Acute cognitive effects of high doses of dextromethorphan relative to triazolam in humans","volume":"128","author":"Carter","year":"2013","journal-title":"Drug Alcohol Depend."},{"key":"10.1016\/j.ejphar.2019.172639_bib9","doi-asserted-by":"crossref","first-page":"656","DOI":"10.1007\/s11481-012-9382-z","article-title":"Inflammation in patients with schizophrenia: the therapeutic benefits of risperidone plus add-on dextromethorphan","volume":"7","author":"Chen","year":"2012","journal-title":"J. Neuroimmune Pharmacol."},{"key":"10.1016\/j.ejphar.2019.172639_bib10","doi-asserted-by":"crossref","first-page":"301","DOI":"10.3727\/096368915X688236","article-title":"PET imaging of serotonin transporters with 4-[(18)F]-ADAM in a parkinsonian rat model with porcine neural xenografts","volume":"25","author":"Chiu","year":"2016","journal-title":"Cell Transplant."},{"key":"10.1016\/j.ejphar.2019.172639_bib11","doi-asserted-by":"crossref","first-page":"333","DOI":"10.1016\/0006-8993(87)90070-9","article-title":"Dextrorphan and dextromethorphan attenuate glutamate neurotoxicity","volume":"403","author":"Choi","year":"1987","journal-title":"Brain Res."},{"key":"10.1016\/j.ejphar.2019.172639_bib12","doi-asserted-by":"crossref","first-page":"280","DOI":"10.2165\/00019053-199507040-00002","article-title":"The defined daily dose as a tool in pharmacoeconomics. Advantages and limitations","volume":"7","author":"Clarke","year":"1995","journal-title":"PharmacoEcon"},{"key":"10.1016\/j.ejphar.2019.172639_bib13","doi-asserted-by":"crossref","first-page":"987","DOI":"10.1111\/bph.14153","article-title":"Experimental design and analysis and their reporting II: updated and simplified guidance for authors and peer reviewers","volume":"175","author":"Curtis","year":"2018","journal-title":"Br. J. Pharmacol."},{"key":"10.1016\/j.ejphar.2019.172639_bib14","doi-asserted-by":"crossref","first-page":"776","DOI":"10.1111\/j.1471-4159.2004.02415.x","article-title":"Effects of 6-hydroxydopamine on primary cultures of substantia nigra: specific damage to dopamine neurons and the impact of glial cell line-derived neurotrophic factor","volume":"89","author":"Ding","year":"2004","journal-title":"J. Neurochem."},{"key":"10.1016\/j.ejphar.2019.172639_bib15","doi-asserted-by":"crossref","first-page":"893","DOI":"10.1002\/mds.26976","article-title":"Trial of dextromethorphan\/quinidine to treat levodopa-induced dyskinesia in Parkinson's disease","volume":"32","author":"Fox","year":"2017","journal-title":"Mov. Disord."},{"key":"10.1016\/j.ejphar.2019.172639_bib16","doi-asserted-by":"crossref","first-page":"224","DOI":"10.1001\/jamainternmed.2018.6112","article-title":"Assessment of use of combined dextromethorphan and quinidine in patients with dementia or Parkinson disease after US food and drug administration approval for pseudobulbar affect","volume":"179","author":"Fralick","year":"2019","journal-title":"JAMA Intern Med"},{"key":"10.1016\/j.ejphar.2019.172639_bib17","doi-asserted-by":"crossref","first-page":"1954","DOI":"10.1096\/fj.03-0109fje","article-title":"Critical role of microglial NADPH oxidase-derived free radicals in the in vitro MPTP model of Parkinson's disease","volume":"17","author":"Gao","year":"2003","journal-title":"FASEB J. : Off. Publ. Federat. Am. Soc. Exp. Biol."},{"key":"10.1016\/j.ejphar.2019.172639_bib18","doi-asserted-by":"crossref","first-page":"115","DOI":"10.1007\/s00259-012-2250-5","article-title":"PET imaging of the brain serotonin transporters (SERT) with N,N-dimethyl-2-(2-amino-4-[18F]fluorophenylthio)benzylamine (4-[18F]-ADAM) in humans: a preliminary study","volume":"40","author":"Huang","year":"2013","journal-title":"Eur. J. Nucl. Med. Mol. Imaging"},{"key":"10.1016\/j.ejphar.2019.172639_bib19","doi-asserted-by":"crossref","first-page":"655","DOI":"10.3727\/000000005783982684","article-title":"In vivo PET measurements with [11C]PE2I to evaluate fetal mesencephalic transplantations to unilateral 6-OHDA-lesioned rats","volume":"14","author":"Inaji","year":"2005","journal-title":"Cell Transplant."},{"key":"10.1016\/j.ejphar.2019.172639_bib20","doi-asserted-by":"crossref","first-page":"47","DOI":"10.1016\/S0014-2999(01)01409-1","article-title":"Effects of dextromethorphan on nocturnal behavior and brain c-Fos expression in adolescent rats","volume":"431","author":"Jahng","year":"2001","journal-title":"Eur. J. Pharmacol."},{"key":"10.1016\/j.ejphar.2019.172639_bib21","series-title":"Dextromethorphan Toxicity","author":"Journey","year":"2019"},{"key":"10.1016\/j.ejphar.2019.172639_bib22","doi-asserted-by":"crossref","first-page":"496","DOI":"10.1111\/jon.12519","article-title":"Noninvasive PK11195-PET image analysis techniques can detect abnormal cerebral microglial activation in Parkinson's disease","volume":"28","author":"Kang","year":"2018","journal-title":"J. Neuroimaging"},{"key":"10.1016\/j.ejphar.2019.172639_bib23","doi-asserted-by":"crossref","first-page":"874","DOI":"10.1111\/j.1460-9568.2008.06062.x","article-title":"Dextromethorphan is protective against sensitized N-methyl-D-aspartate receptor-mediated excitotoxic brain damage in the developing mouse brain","volume":"27","author":"Keller","year":"2008","journal-title":"Eur. J. Neurosci."},{"key":"10.1016\/j.ejphar.2019.172639_bib24","doi-asserted-by":"crossref","first-page":"139","DOI":"10.1016\/j.brainres.2010.02.031","article-title":"Resveratrol attenuates 6-hydroxydopamine-induced oxidative damage and dopamine depletion in rat model of Parkinson's disease","volume":"1328","author":"Khan","year":"2010","journal-title":"Brain Res."},{"key":"10.1016\/j.ejphar.2019.172639_bib25","doi-asserted-by":"crossref","first-page":"94","DOI":"10.1016\/j.neuroimage.2018.01.021","article-title":"Compensatory dopaminergic-cholinergic interactions in conflict processing: evidence from patients with Parkinson\u2019s disease","volume":"190","author":"Kim","year":"2019","journal-title":"Neuroimage"},{"key":"10.1016\/j.ejphar.2019.172639_bib26","doi-asserted-by":"crossref","first-page":"489","DOI":"10.1096\/fj.04-2555com","article-title":"Femtomolar concentrations of dextromethorphan protect mesencephalic dopaminergic neurons from inflammatory damage","volume":"19","author":"Li","year":"2005","journal-title":"FASEB J. : Off. Publ. Federat. Am. Soc. Exp. Biol."},{"key":"10.1016\/j.ejphar.2019.172639_bib27","doi-asserted-by":"crossref","first-page":"1259","DOI":"10.1016\/j.neuroimage.2009.07.072","article-title":"Study on the neuroprotective effect of fluoxetine against MDMA-induced neurotoxicity on the serotonin transporter in rat brain using micro-PET","volume":"49","author":"Li","year":"2010","journal-title":"Neuroimage"},{"key":"10.1016\/j.ejphar.2019.172639_bib28","doi-asserted-by":"crossref","first-page":"117","DOI":"10.1002\/mds.27183","article-title":"(11) C-PE2I and (18) F-Dopa PET for assessing progression rate in Parkinson's: a longitudinal study","volume":"33","author":"Li","year":"2018","journal-title":"Mov. Disord."},{"key":"10.1016\/j.ejphar.2019.172639_bib29","doi-asserted-by":"crossref","first-page":"3390","DOI":"10.1007\/s11064-017-2379-5","article-title":"Neuroprotective activities of spirulina platensis in the 6-OHDA model of Parkinson's disease are related to its anti-inflammatory effects","volume":"42","author":"Lima","year":"2017","journal-title":"Neurochem. Res."},{"key":"10.1016\/j.ejphar.2019.172639_bib30","first-page":"673","article-title":"Characterization of the binding sites for 123I-ADAM and the relationship to the serotonin transporter in rat and mouse brains using quantitative autoradiography","volume":"45","author":"Lin","year":"2004","journal-title":"J. Nucl. Med. : Off. Publ., Soc. Nucl. Med."},{"key":"10.1016\/j.ejphar.2019.172639_bib31","doi-asserted-by":"crossref","first-page":"1685","DOI":"10.1111\/j.1538-7836.2008.03082.x","article-title":"Treatment with dextromethorphan improves endothelial function, inflammation and oxidative stress in male heavy smokers","volume":"6","author":"Liu","year":"2008","journal-title":"J. Thromb. Haemost."},{"key":"10.1016\/j.ejphar.2019.172639_bib32","doi-asserted-by":"crossref","first-page":"212","DOI":"10.1124\/jpet.102.043166","article-title":"Dextromethorphan protects dopaminergic neurons against inflammation-mediated degeneration through inhibition of microglial activation","volume":"305","author":"Liu","year":"2003","journal-title":"J. Pharmacol. Exp. Ther."},{"key":"10.1016\/j.ejphar.2019.172639_bib33","doi-asserted-by":"crossref","first-page":"131","DOI":"10.1162\/153535003322556877","article-title":"AMIDE: a free software tool for multimodality medical image analysis","volume":"2","author":"Loening","year":"2003","journal-title":"Mol. Imaging"},{"key":"10.1016\/j.ejphar.2019.172639_bib34","doi-asserted-by":"crossref","first-page":"687","DOI":"10.1016\/j.neuroimage.2008.12.060","article-title":"Validation of 4-[18F]-ADAM as a SERT imaging agent using micro-PET and autoradiography","volume":"45","author":"Ma","year":"2009","journal-title":"Neuroimage"},{"key":"10.1016\/j.ejphar.2019.172639_bib35","doi-asserted-by":"crossref","first-page":"38695","DOI":"10.1038\/srep38695","article-title":"Effects of dextromethorphan on MDMA-induced serotonergic aberration in the brains of non-human primates using [(123)I]-ADAM\/SPECT","volume":"6","author":"Ma","year":"2016","journal-title":"Sci. Rep."},{"key":"10.1016\/j.ejphar.2019.172639_bib36","doi-asserted-by":"crossref","first-page":"1497","DOI":"10.1001\/jamaneurol.2016.3850","article-title":"Trends in the incidence of Parkinson disease","volume":"73","author":"Macerollo","year":"2016","journal-title":"JAMA Neurol"},{"key":"10.1016\/j.ejphar.2019.172639_bib37","doi-asserted-by":"crossref","first-page":"391","DOI":"10.4103\/1673-5374.153686","article-title":"A new look at auranofin, dextromethorphan and rosiglitazone for reduction of glia-mediated inflammation in neurodegenerative diseases","volume":"10","author":"Madeira","year":"2015","journal-title":"Neural Regen Res"},{"key":"10.1016\/j.ejphar.2019.172639_bib38","doi-asserted-by":"crossref","first-page":"9","DOI":"10.1016\/0014-2999(91)90062-U","article-title":"Inhibition of K(+)-evoked [3H]D-aspartate release and neuronal calcium influx by verapamil, diltiazem and dextromethorphan: evidence for non-L\/non-N voltage-sensitive calcium channels","volume":"192","author":"Mangano","year":"1991","journal-title":"Eur. J. Pharmacol."},{"key":"10.1016\/j.ejphar.2019.172639_bib39","doi-asserted-by":"crossref","first-page":"1285","DOI":"10.1212\/WNL.38.8.1285","article-title":"Reactive microglia are positive for HLA-DR in the substantia nigra of Parkinson's and Alzheimer's disease brains","volume":"38","author":"McGeer","year":"1988","journal-title":"Neurology"},{"key":"10.1016\/j.ejphar.2019.172639_bib40","doi-asserted-by":"crossref","first-page":"428","DOI":"10.1002\/jnr.490260405","article-title":"Toxicity of 6-hydroxydopamine and dopamine for dopaminergic neurons in culture","volume":"26","author":"Michel","year":"1990","journal-title":"J. Neurosci. Res."},{"key":"10.1016\/j.ejphar.2019.172639_bib41","doi-asserted-by":"crossref","first-page":"50","DOI":"10.17116\/jnevro201811806250","article-title":"[Parkinson's disease and glutamate excitotoxicity]","volume":"118","author":"Mironova","year":"2018","journal-title":"Zh. Nevrol. Psikhiatr. Im. S S Korsakova"},{"key":"10.1016\/j.ejphar.2019.172639_bib42","doi-asserted-by":"crossref","first-page":"242","DOI":"10.1002\/mds.870090226","article-title":"N-methyl-D-aspartate (NMDA) antagonist and Parkinson's disease: a pilot study with dextromethorphan","volume":"9","author":"Montastruc","year":"1994","journal-title":"Mov. Disord."},{"key":"10.1016\/j.ejphar.2019.172639_bib43","doi-asserted-by":"crossref","first-page":"27","DOI":"10.4103\/0976-0105.177703","article-title":"A simple practice guide for dose conversion between animals and human","volume":"7","author":"Nair","year":"2016","journal-title":"J. Basic Clin. Pharm."},{"key":"10.1016\/j.ejphar.2019.172639_bib44","doi-asserted-by":"crossref","first-page":"54","DOI":"10.1254\/jphs.11008FP","article-title":"Dextromethorphan inhibits the glutamatergic synaptic transmission in the nucleus tractus solitarius of Guinea pigs","volume":"116","author":"Ohi","year":"2011","journal-title":"J. Pharmacol. Sci."},{"key":"10.1016\/j.ejphar.2019.172639_bib45","doi-asserted-by":"crossref","first-page":"141","DOI":"10.1016\/j.neuroscience.2017.08.023","article-title":"An altered blood-brain barrier contributes to brain iron accumulation and neuroinflammation in the 6-OHDA rat model of Parkinson's disease","volume":"362","author":"Olmedo-Diaz","year":"2017","journal-title":"Neuroscience"},{"key":"10.1016\/j.ejphar.2019.172639_bib46","series-title":"The Rat Brain in Stereotaxic Coordinates","author":"Paxinos","year":"2013"},{"key":"10.1016\/j.ejphar.2019.172639_bib47","doi-asserted-by":"crossref","first-page":"625","DOI":"10.1016\/j.apradiso.2007.11.009","article-title":"An automated synthesis of N,N-dimethyl-2-(2-amino-4-[18F]fluorophenylthio)benzylamine (4-[18F]-ADAM) for imaging serotonin transporters","volume":"66","author":"Peng","year":"2008","journal-title":"Appl. Radiat. Isot."},{"key":"10.1016\/j.ejphar.2019.172639_bib48","doi-asserted-by":"crossref","first-page":"3704","DOI":"10.3892\/mmr.2015.3830","article-title":"Dextromethorphan provides neuroprotection via anti-inflammatory and anti-excitotoxicity effects in the cortex following traumatic brain injury","volume":"12","author":"Pu","year":"2015","journal-title":"Mol. Med. Rep."},{"key":"10.1016\/j.ejphar.2019.172639_bib49","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1007\/s00213-012-2680-6","article-title":"High doses of dextromethorphan, an NMDA antagonist, produce effects similar to classic hallucinogens","volume":"223","author":"Reissig","year":"2012","journal-title":"Psychopharmacology"},{"key":"10.1016\/j.ejphar.2019.172639_bib50","doi-asserted-by":"crossref","first-page":"16","DOI":"10.1002\/syn.890170103","article-title":"Relationship between asymmetries in striatal dopamine release and the direction of amphetamine-induced rotation during the first week following a unilateral 6-OHDA lesion of the substantia nigra","volume":"17","author":"Robinson","year":"1994","journal-title":"Synapse"},{"key":"10.1016\/j.ejphar.2019.172639_bib51","doi-asserted-by":"crossref","first-page":"831","DOI":"10.1016\/0306-4522(92)90271-3","article-title":"Effects of 6-hydroxydopamine lesions of the prefrontal cortex on tyrosine hydroxylase activity in mesolimbic and nigrostriatal dopamine systems","volume":"48","author":"Rosin","year":"1992","journal-title":"Neuroscience"},{"key":"10.1016\/j.ejphar.2019.172639_bib52","doi-asserted-by":"crossref","first-page":"4843","DOI":"10.1016\/j.bmcl.2009.06.032","article-title":"Synthesis, radiolabeling and preliminary in vivo evaluation of [18F]FE-PE2I, a new probe for the dopamine transporter","volume":"19","author":"Schou","year":"2009","journal-title":"Bioorg. Med. Chem. Lett"},{"key":"10.1016\/j.ejphar.2019.172639_bib53","doi-asserted-by":"crossref","first-page":"83","DOI":"10.2174\/138920008783331095","article-title":"Effect of the NMDA-receptor antagonist dextromethorphan in infant rat pneumococcal meningitis","volume":"9","author":"Sellner","year":"2008","journal-title":"Curr. Drug Metabol."},{"key":"10.1016\/j.ejphar.2019.172639_bib54","doi-asserted-by":"crossref","first-page":"56","DOI":"10.1016\/j.pbb.2009.07.006","article-title":"Neuroprotective profile of dextromethorphan in an experimental model of penetrating ballistic-like brain injury","volume":"94","author":"Shear","year":"2009","journal-title":"Pharmacol., Biochem. Behav."},{"key":"10.1016\/j.ejphar.2019.172639_bib55","doi-asserted-by":"crossref","first-page":"92","DOI":"10.1016\/j.euroneuro.2015.11.001","article-title":"Evaluation of brain SERT occupancy by resveratrol against MDMA-induced neurobiological and behavioral changes in rats: a 4-[(1)(8)F]-ADAM\/small-animal PET study","volume":"26","author":"Shih","year":"2016","journal-title":"Eur. Neuropsychopharmacol. :J Eur. Coll. Neuropsychopharmacol."},{"key":"10.1016\/j.ejphar.2019.172639_bib56","doi-asserted-by":"crossref","first-page":"137","DOI":"10.1254\/jphs.11R02CR","article-title":"Neuropsychotoxic and neuroprotective potentials of dextromethorphan and its analogs","volume":"116","author":"Shin","year":"2011","journal-title":"J. Pharmacol. Sci."},{"key":"10.1016\/j.ejphar.2019.172639_bib57","doi-asserted-by":"crossref","first-page":"22","DOI":"10.1254\/jphs.FM0070177","article-title":"Neuropsychotoxicity of abused drugs: potential of dextromethorphan and novel neuroprotective analogs of dextromethorphan with improved safety profiles in terms of abuse and neuroprotective effects","volume":"106","author":"Shin","year":"2008","journal-title":"J. Pharmacol. Sci."},{"key":"10.1016\/j.ejphar.2019.172639_bib58","first-page":"1","article-title":"Interpretation of animal dose and human equivalent dose for drug development","volume":"31","author":"Shin","year":"2010","journal-title":"J. Kor. Orient. Med."},{"key":"10.1016\/j.ejphar.2019.172639_bib59","doi-asserted-by":"crossref","first-page":"1268","DOI":"10.1016\/j.neuropharm.2012.07.029","article-title":"Fibroblast growth factor-20 protects against dopamine neuron loss in vitro and provides functional protection in the 6-hydroxydopamine-lesioned rat model of Parkinson's disease","volume":"63","author":"Sleeman","year":"2012","journal-title":"Neuropharmacology"},{"key":"10.1016\/j.ejphar.2019.172639_bib60","doi-asserted-by":"crossref","first-page":"225","DOI":"10.1017\/S109285291300062X","article-title":"Mechanism of action of dextromethorphan\/quinidine:comparison with ketamine","volume":"18","author":"Stahl","year":"2013","journal-title":"CNS Spectr."},{"key":"10.1016\/j.ejphar.2019.172639_bib61","doi-asserted-by":"crossref","first-page":"803","DOI":"10.1016\/S0091-3057(02)01080-8","article-title":"Effects of dextromethorphan on dopamine release in the nucleus accumbens: interactions with morphine","volume":"74","author":"Steinmiller","year":"2003","journal-title":"Pharmacol., Biochem. Behav."},{"key":"10.1016\/j.ejphar.2019.172639_bib62","doi-asserted-by":"crossref","first-page":"206","DOI":"10.1002\/jlcr.2927","article-title":"An efficient one-step radiosynthesis of [18F]FE-PE2I, a PET radioligand for imaging of dopamine transporters","volume":"55","author":"Stepanov","year":"2012","journal-title":"J. Label. Comp. Radiopharm."},{"key":"10.1016\/j.ejphar.2019.172639_bib63","doi-asserted-by":"crossref","first-page":"301","DOI":"10.1016\/0006-8993(91)90635-9","article-title":"Effects of 6-hydroxydopamine lesions of the nigrostriatal pathway on striatal serotonin innervation in adult rats","volume":"562","author":"Takeuchi","year":"1991","journal-title":"Brain Res."},{"key":"10.1016\/j.ejphar.2019.172639_bib64","doi-asserted-by":"crossref","first-page":"298","DOI":"10.1016\/S0006-8993(03)02538-1","article-title":"Dextromethorphan prevents the diethyldithiocarbamate enhancement of 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine toxicity in mice","volume":"973","author":"Vaglini","year":"2003","journal-title":"Brain Res."},{"key":"10.1016\/j.ejphar.2019.172639_bib65","doi-asserted-by":"crossref","first-page":"132","DOI":"10.2967\/jnumed.110.077651","article-title":"Kinetic analysis and quantification of the dopamine transporter in the nonhuman primate brain with 11C-PE2I and 18F-FE-PE2I","volume":"52","author":"Varrone","year":"2011","journal-title":"J. Nucl. Med. : Offic. Publ., Soc. Nucl. Med."},{"key":"10.1016\/j.ejphar.2019.172639_bib66","doi-asserted-by":"crossref","first-page":"203","DOI":"10.1212\/WNL.51.1.203","article-title":"Dextromethorphan improves levodopa-induced dyskinesias in Parkinson's disease","volume":"51","author":"Verhagen Metman","year":"1998","journal-title":"Neurology"},{"key":"10.1016\/j.ejphar.2019.172639_bib67","doi-asserted-by":"crossref","first-page":"1295","DOI":"10.3727\/096368912X658683","article-title":"PET imaging of serotonin transporters with 4-[18F]-ADAM in a Parkinsonian rat model","volume":"22","author":"Weng","year":"2013","journal-title":"Cell Transplant."},{"key":"10.1016\/j.ejphar.2019.172639_bib68","doi-asserted-by":"crossref","first-page":"272","DOI":"10.1097\/NRL.0b013e3180f60bd8","article-title":"Dextromethorphan as a potential neuroprotective agent with unique mechanisms of action","volume":"13","author":"Werling","year":"2007","journal-title":"The Neurologist"},{"key":"10.1016\/j.ejphar.2019.172639_bib69","first-page":"233","article-title":"The defined daily dose system (DDD) for drug utilization review","volume":"21","author":"Wertheimer","year":"1986","journal-title":"Hosp. Pharm."},{"key":"10.1016\/j.ejphar.2019.172639_bib70","doi-asserted-by":"crossref","first-page":"3494","DOI":"10.1007\/s12035-016-9786-5","article-title":"Prevention of hippocampal neuronal damage and cognitive function deficits in vascular dementia by dextromethorphan","volume":"53","author":"Xu","year":"2016","journal-title":"Mol. Neurobiol."},{"key":"10.1016\/j.ejphar.2019.172639_bib71","doi-asserted-by":"crossref","first-page":"589","DOI":"10.1096\/fj.03-0983fje","article-title":"Neuroprotective effect of dextromethorphan in the MPTP Parkinson's disease model: role of NADPH oxidase","volume":"18","author":"Zhang","year":"2004","journal-title":"FASEB J. : Off. Publ. Federat. Am. Soc. Exp. Biol."}],"container-title":["European Journal of Pharmacology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0014299919305916?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0014299919305916?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2026,4,28]],"date-time":"2026-04-28T19:44:29Z","timestamp":1777405469000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0014299919305916"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2019,11]]},"references-count":71,"alternative-id":["S0014299919305916"],"URL":"https:\/\/doi.org\/10.1016\/j.ejphar.2019.172639","relation":{},"ISSN":["0014-2999"],"issn-type":[{"value":"0014-2999","type":"print"}],"subject":[],"published":{"date-parts":[[2019,11]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"The effect of dextromethorphan use in Parkinson's disease: A 6-hydroxydopamine rat model and population-based study","name":"articletitle","label":"Article Title"},{"value":"European Journal of Pharmacology","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.ejphar.2019.172639","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2019 Elsevier B.V. All rights reserved.","name":"copyright","label":"Copyright"}],"article-number":"172639"}}